Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma.
STAR Protoc
; 1(3): 100174, 2020 12 18.
Article
em En
| MEDLINE
| ID: mdl-33377068
ABSTRACT
Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Glioblastoma
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Receptores de Antígenos Quiméricos
Tipo de estudo:
Guideline
Limite:
Animals
/
Humans
Idioma:
En
Revista:
STAR Protoc
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Canadá